Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

Oncogene volume 28, pages 2903–2909 (2009)Cite this article

Abstract

The identification of molecular markers, useful for therapeutic decisions in pancreatic cancer patients, is crucial for advances in disease management. Gemcitabine, although a cornerstone of current therapy, has limited efficacy. RRM1 is a key molecule for gemcitabine efficacy and is also involved in tumor progression. We determined in situ RRM1 and excision repair cross complementation group 1 (ERCC1) protein levels in 68 pancreatic cancer patients. All had R0 resections without preoperative therapy. Protein levels were determined by automated quantitative analysis (AQUA), a fluorescence-based immunohistochemical method. The relationship between protein expressions and clinical outcomes, including response to gemcitabine at the time of disease recurrence, was determined. Patients with high RRM1 showed significantly better overall survival than patients with low expression (P=0.0196). There was a trend toward better overall survival for patient with high ERCC1 (P=0.0552). When both markers were considered together, patients with both high RRM1 and ERCC1 faired the best in terms of overall and disease-free survival (P=0.0066, P=0.0127). In addition, treatment benefit from gemcitabine in patients with disease recurrence was observed only in patients with low RRM1. The combination of RRM1 and ERCC1 expression is prognostic in pancreatic cancer patients after a complete resection. On disease recurrence, only patients with low RRM1 derive benefit from gemcitabine.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Bachem MG, Schunemann M, Ramadani M, Siech M, Beger H, Buck A et al. (2005). Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128: 907–921.

    Article  CAS  PubMed  Google Scholar 

  • Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A et al. (2006). RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24: 4731–4737.

    Article  CAS  PubMed  Google Scholar 

  • Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G et al. (2004). RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 22: 1878–1885.

    Article  CAS  PubMed  Google Scholar 

  • Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I et al. (2005). in vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 65: 9510–9516.

    Article  CAS  PubMed  Google Scholar 

  • Boeck S, Heinemann V . (2008). Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol 26: 1178–1179; author reply 1179.

    Article  PubMed  Google Scholar 

  • Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413.

    Article  CAS  PubMed  Google Scholar 

  • Camp RL, Chung GG, Rimm DL . (2002). Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8: 1323–1327.

    Article  CAS  PubMed  Google Scholar 

  • Cao MY, Lee Y, Feng NP, Xiong K, Jin H, Wang M et al. (2003). Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin Cancer Res 9: 4553–4561.

    CAS  PubMed  Google Scholar 

  • Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E et al. (2008). Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 9: 39–44.

    Article  CAS  PubMed  Google Scholar 

  • Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV et al. (2006). ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17: 1818–1825.

    Article  CAS  PubMed  Google Scholar 

  • Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA . (2004). An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64: 3761–3766.

    Article  CAS  PubMed  Google Scholar 

  • Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I, Gandhi V et al. (1999). Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 106: 78–85.

    Article  CAS  PubMed  Google Scholar 

  • Fan H, Huang A, Villegas C, Wright JA . (1997). The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci USA 94: 13181–13186.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gautam A, Bepler G . (2006). Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 66: 6497–6502.

    Article  CAS  PubMed  Google Scholar 

  • Gautam A, Li ZR, Bepler G . (2003). RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 22: 2135–2142.

    Article  CAS  PubMed  Google Scholar 

  • Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S et al. (2006). Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66: 3928–3935.

    Article  CAS  PubMed  Google Scholar 

  • Goan YG, Zhou B, Hu E, Mi S, Yen Y . (1999). Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59: 4204–4207.

    CAS  PubMed  Google Scholar 

  • Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A et al. (2006). Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946–3952.

    Article  CAS  PubMed  Google Scholar 

  • Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J et al. (2007). Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25: 2212–2217.

    Article  CAS  PubMed  Google Scholar 

  • Hurta RA, Wright JA . (1992). Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent. J Biol Chem 267: 7066–7071.

    CAS  PubMed  Google Scholar 

  • Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA et al. (2007). Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25: 319–325.

    Article  PubMed  Google Scholar 

  • Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon II JE et al. (2005). High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11: 2215–2221.

    Article  PubMed  Google Scholar 

  • Jung CP, Motwani MV, Schwartz GK . (2001). Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7: 2527–2536.

    CAS  PubMed  Google Scholar 

  • Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I . (1993). An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 72: 2118–2123.

    Article  CAS  PubMed  Google Scholar 

  • Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH et al. (2008). Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 14: 4225–4231.

    Article  CAS  PubMed  Google Scholar 

  • Li D, Xie K, Wolff R, Abbruzzese JL . (2004). Pancreatic cancer. Lancet 363: 1049–1057.

    Article  CAS  PubMed  Google Scholar 

  • Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL et al. (2000). Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20: 645–652.

    CAS  PubMed  Google Scholar 

  • Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K et al. (1998). ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309–316.

    Article  CAS  PubMed  Google Scholar 

  • Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960–1966.

    Article  CAS  PubMed  Google Scholar 

  • Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S et al. (2007). Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120: 1355–1363.

    Article  CAS  PubMed  Google Scholar 

  • Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF et al. (2004). The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24: 5776–5787.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nitecki SS, Sarr MG, Colby TV, van Heerden JA . (1995). Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221: 59–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al. (2007). Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 297: 267–277.

    Article  CAS  PubMed  Google Scholar 

  • Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S et al. (2008). A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61: 615–621.

    Article  CAS  PubMed  Google Scholar 

  • Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V et al. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983–991.

    Article  CAS  PubMed  Google Scholar 

  • Plunkett W, Huang P, Searcy CE, Gandhi V . (1996). Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23: 3–15.

    CAS  PubMed  Google Scholar 

  • Reardon JT, Vaisman A, Chaney SG, Sancar A . (1999). Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59: 3968–3971.

    CAS  PubMed  Google Scholar 

  • Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C et al. (2004). Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10: 1318–1325.

    Article  CAS  PubMed  Google Scholar 

  • Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris III HA et al. (1996). A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7: 347–353.

    Article  CAS  PubMed  Google Scholar 

  • Saif MW . (2008). New developments in the treatment of pancreatic cancer. Highlights from the ‘44th ASCO Annual Meeting’. Chicago, IL, USA. May 30–June 3, 2008. JOP 9: 391–397.

    PubMed  Google Scholar 

  • Sato N, Maehara N, Goggins M . (2004). Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 64: 6950–6956.

    Article  CAS  PubMed  Google Scholar 

  • Sener SF, Fremgen A, Menck HR, Winchester DP . (1999). Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg 189: 1–7.

    Article  CAS  PubMed  Google Scholar 

  • Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD et al. (2001). ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298–4304.

    Article  CAS  PubMed  Google Scholar 

  • Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C et al. (2007). Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 25: 2741–2746.

    Article  CAS  PubMed  Google Scholar 

  • Staley CA, Lee JE, Cleary KR, Abbruzzese JL, Fenoglio CJ, Rich TA et al. (1996). Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 171: 118–124; discussion 124–5.

    Article  CAS  PubMed  Google Scholar 

  • Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C . (2005). An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68: 171–178.

    Article  CAS  PubMed  Google Scholar 

  • Wright JA, Chan AK, Choy BK, Hurta RA, McClarty GA, Tagger AY . (1990). Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis. Biochem Cell Biol 68: 1364–1371.

    Article  CAS  PubMed  Google Scholar 

  • Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G . (2007). DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356: 800–808.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was partially supported by National Institutes of Health (NIH) grant R01-CA129343 to GB and by a grant-in-aid for cancer research from the Ministry of Culture and Science of Japan.

Author information

Authors and Affiliations

  1. Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

    H Akita, Y Takeda, C Kim, N Kittaka, S Kobayashi, S Marubashi, I Takemasa, H Nagano, K Dono, M Monden, M Mori & Y Doki

  2. Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA

    Z Zheng & G Bepler

  3. Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan

    S Nakamori

Authors
  1. H Akita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Kittaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Marubashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I Takemasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H Nagano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K Dono
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Nakamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Monden
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Y Doki
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. G Bepler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Takeda.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Akita, H., Zheng, Z., Takeda, Y. et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 28, 2903–2909 (2009). https://doi.org/10.1038/onc.2009.158

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2009.158

Keywords

This article is cited by

Search

Advanced search

Quick links